Le T, Leis A, Pahwa P, Wright K, Ali K, Reeder B, Kinderchuck M, Ward K
Department of Obstetrics and Gynaecology, Division of Gynaecologic Oncology, University of Ottawa, Ottawa, ON.
J Obstet Gynaecol Can. 2004 Jul;26(7):627-31. doi: 10.1016/s1701-2163(16)30609-0.
(1) To examine the quality of life (QOL) of caregivers of women undergoing chemotherapy for advanced ovarian cancers, and (2) to correlate the QOL measures of caregivers to those of the women undergoing chemotherapy.
Over a 9-month period, all women undergoing chemotherapy for ovarian cancer at the Saskatoon Cancer Centre, and their caregivers, were offered participation. Two well-validated instruments were used to measure the "quality of life" concept. Women with ovarian cancer completed the Functional Assessment of Cancer Therapy--Ovarian (FACT-O) questionnaire in the clinic prior to each course of chemotherapy. Each caregiver completed a Caregiver Quality of Life Index--Cancer (CQOL-C) questionnaire at home at the start and conclusion of each chemotherapy regimen (cycle 1 and after the last chemotherapy treatment). The demographics of the caregivers were described. A paired t test was used to detect changes to caregivers' QOL scores before and after chemotherapy treatment. Correlation analysis was carried out to examine the relationship between the caregivers' total QOL scores and the various subscale and total scores of the FACT-O questionnaires completed by the women with ovarian cancer. Multivariate regression models were constructed to examine the relative importance of each of the QOL domain measures of the woman with cancer in predicting the effect on her caregiver's QOL.
Thirty different patient-caregiver pairs participated in the study, providing 50 separate assessments since not all pairs had completed the post-chemotherapy assessments. There was improvement (P <.05) in the caregiver's QOL scores at the conclusion of the chemotherapy treatment compared to the baseline assessments. The improvement was unrelated to the performance status or response to chemotherapy of the woman undergoing treatment. There was also a correlation (P <.05) between an increase in a caregiver's distress and worsening scores in the "emotional," "functional," and "concerns" QOL domain assessments of the woman undergoing treatment. Stepwise regression analysis showed the "concerns" score, measuring specific ovarian cancer-related symptoms, to be the only predictor of a caregiver's distress (P <.05).
Standard chemotherapy for ovarian cancer does not worsen a caregiver's QOL. There is a direct relationship between the QOL of women with cancer and that of their caregivers. Future research is required to identify how best to integrate the results of QOL assessments in cancer treatment protocols and to examine the long-term effects of ovarian cancer and its treatment on both caregivers and the women for whom they care.
(1)研究晚期卵巢癌化疗女性患者照顾者的生活质量(QOL),(2)将照顾者的生活质量测量结果与接受化疗的女性患者的生活质量测量结果进行关联分析。
在9个月的时间里,邀请了萨斯卡通癌症中心所有正在接受卵巢癌化疗的女性及其照顾者参与研究。使用两种经过充分验证的工具来测量“生活质量”概念。卵巢癌女性患者在每次化疗疗程前在诊所完成癌症治疗功能评估——卵巢癌(FACT-O)问卷。每位照顾者在每个化疗方案开始和结束时(第1周期和最后一次化疗治疗后)在家中完成照顾者生活质量指数——癌症(CQOL-C)问卷。描述了照顾者的人口统计学特征。采用配对t检验来检测化疗治疗前后照顾者生活质量得分的变化。进行相关分析以研究照顾者的总生活质量得分与卵巢癌女性患者完成的FACT-O问卷的各个子量表得分及总分之间的关系。构建多元回归模型以研究癌症女性患者生活质量各领域测量指标在预测对其照顾者生活质量影响方面的相对重要性。
30对不同的患者-照顾者对参与了研究,由于并非所有对都完成了化疗后评估,因此提供了50次单独评估。与基线评估相比,化疗治疗结束时照顾者的生活质量得分有所改善(P<.05)。这种改善与接受治疗的女性的表现状态或对化疗的反应无关。在接受治疗的女性的“情感”、“功能”和“担忧”生活质量领域评估中,照顾者的痛苦增加与女性得分恶化之间也存在相关性(P<.05)。逐步回归分析表明,测量特定卵巢癌相关症状的“担忧”得分是照顾者痛苦的唯一预测指标(P<.05)。
卵巢癌的标准化化疗不会使照顾者的生活质量恶化。癌症女性患者及其照顾者的生活质量之间存在直接关系。未来需要开展研究,以确定如何最好地将生活质量评估结果纳入癌症治疗方案,并研究卵巢癌及其治疗对照顾者和她们所照顾女性的长期影响。